CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

CEL-SCI Stock Performance

Shares of NYSE CVM opened at $0.40 on Wednesday. CEL-SCI has a 1 year low of $0.37 and a 1 year high of $3.08. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. The company’s fifty day moving average price is $0.64 and its 200 day moving average price is $0.96. The company has a market capitalization of $26.42 million, a PE ratio of -0.69 and a beta of 0.65.

Hedge Funds Weigh In On CEL-SCI

A number of large investors have recently bought and sold shares of CVM. Calton & Associates Inc. acquired a new stake in shares of CEL-SCI in the third quarter valued at about $50,000. Black Diamond Financial LLC lifted its stake in CEL-SCI by 35.8% in the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after buying an additional 19,000 shares in the last quarter. Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI in the 3rd quarter worth about $98,000. Thoroughbred Financial Services LLC increased its stake in CEL-SCI by 140.9% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after buying an additional 80,001 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after acquiring an additional 40,000 shares during the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.